Antithrombotic therapy for secondary stroke prevention

CONTINUUM Lifelong Learning in Neurology

Volumn 17, Issue 6, 2011, Pages 1255-1266

  Alberts, Mark J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450 2C19; DABIGATRAN; DIPYRIDAMOLE; RIVAROXABAN; TICLOPIDINE; WARFARIN;

AGED; ANTICOAGULANT THERAPY; APHASIA; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CASE REPORT; CENTRAL NERVOUS SYSTEM BLEEDING; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSPHAGIA; EMBOLISM; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SINGLE DRUG DOSE; SKIN BRUISING; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT WITHDRAWAL; WEAKNESS;

EID: 84856120995     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000410034.19230.03     Document Type: Review

References (29)

1. Furie KL, Kasner SE, Adams RJ, et al. American Association Stroke Council, Council on Cardiovascular Nursing, Council in Clinical Cardiology, Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42(1): 227-276.
2. Weimar C, Weber R, Diener HC. Antithrombotic medication for stroke prevention. Expert Rev Cardiovasc Ther 2009; 7(10): 1245-1254.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329): 71-86.
4. Alberts MJ, Bergman DL, Molner E, et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004; 35(1): 175-178. (Pubitemid 38057615)
5. Hovens MM, Snoep JD, Eikenboom JC, et al. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007; 153(2): 175-181. (Pubitemid 46096871)
6. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005; 46(6): 986-993. (Pubitemid 41316504)
7. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348(9038): 1329-1339.
8. Yusuf S, Zhao F, Mehta SR, et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345(7): 494-502. (Pubitemid 32758501)
9. Ringleb PA, Bhatt DL, Hirsch AT, et al; Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events Investigators. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004; 35(2): 528-532. (Pubitemid 38174442)
10. Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90(6): 625-628. (Pubitemid 35264538)
11. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360(4): 354-362.
12. Paré G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010; 363(18): 1704-1714.
13. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301(9): 937-944.
14. Bhatt DL, Cryer BL, Contant CF, et al; COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363(20): 1909-1917.
15. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143(1-2): 1-13. (Pubitemid 26402780)
16. Halkes PH, van Gijn J, Kappelle LJ, et al. ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367(9523): 1665-1673.
17. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364(9431): 331-337.
18. Sacco RL, Diener HC, Yusuf S, et al; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359(12): 1238-1251.
19. Hackam DG, Spence JD. Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke 2007; 38: 1881-1885. (Pubitemid 46847263)
20. Bhatt DL, Fox KA, Hacke W, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354(16): 1706-1717.
21. García Rodríguez LA, Cea Soriano L, Hill C, Johansson S. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology 2011; 76(8): 740-746.
22. Wann LS, Curtis AB, January CT, et al; 2011 Writing Group Members; 2006 Writing Committee Members; ACCF/AHA Task Force Members. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123(1): 104-123.
23. Albers GW, Amarenco P, Easton JD, et al; American College of Chest Physicians. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-based clinical practice guidelines (8th edition). Chest 2008; 133(6 suppl): 630S-669S. (Pubitemid 351892974)
24. Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 2008; 28(11): 1354-1373.
25. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36(2): 386-399. (Pubitemid 351185753)
26. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361(12): 1139-1151.
27. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103(6): 1116-1127.
28. Connolly SJ, Eikelboom J, Joyner C, et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364(9): 806-817.
29. Liakishev AA. [Dabigatran versus warfarin in the treatment of acute venous thromboembolism. Results of the RE-COVER study]. Kardiologiia 2010; 50(3): 80-81.